NCT01182142View on ClinicalTrials.gov

Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

August 31, 2010

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Capecitabine

1,250 mg/m2 orally twice a day, days 1-14

Trial Locations (1)

Unknown

Natalia Petenko, Moscow

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER

NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | Biotech Hunter | Biotech Hunter